Better Health for All

Bioventus's core business is dedicated to developing and commercializing clinically differentiated, cost-effective treatments for bone and joint healing, including bone graft substitutes, bone growth stimulators, and HA joint fluid therapy, indicating that its entire business is devoted to health improvement. However, the company has faced challenges in other areas. There was one Class 2 product recall (EXOGEN Ultrasound Coupling Gel on January 9, 2021) within the past three years.

Litigation alleged that Bioventus misrepresented the impact of a Medicare pricing shift on key products and concealed deficiencies in internal controls over financial reporting and disclosure, resulting in a $15.25 million settlement. The company offers a Patient Assistance Program providing three products (SUPARTZ FX, GELSYN-3, and DUROLANE) at no cost to US residents earning below 300% of the Federal Poverty Level who lack sufficient insurance. Bioventus supports Investigator Initiated Studies (IIS) and requires IRB approval for clinical studies and adherence to national ethical guidelines for pre-clinical studies, with an additional ethical review by its committee, but currently, no funds are available for IIS. The company's medical education efforts include clinical association partnerships, peer-to-peer consultation, and an online platform, Bioventus Academy. Its grants and charitable donations committee considers requests from not-for-profit institutions for public health treatment, scientific research, and medical education.

Fair Money & Economic Opportunity

Bioventus Inc. is a medical technology company focused on treatments for bone and joint healing. The company does not offer lending, deposit, or other financial services to consumers.

While it operates patient assistance programs for its medical products, these are not financial services. Therefore, all KPIs related to financial services, such as underserved client share, pricing fairness, exploitative fee exposure, inclusion initiatives, data accessibility, fair lending compliance, wealth building outcomes, financial literacy initiatives, debt burden ratio, geographic inclusion, and product simplicity, are not applicable as the company's core business lies outside finance.

Fair Trade & Ethical Sourcing

No specific, quantifiable evidence was found across the provided articles for any of the KPIs related to Fair Trade & Ethical Sourcing. Information regarding fair-trade certification, audit frequency, forced or child labor incidents, supply chain traceability, remediation speed, ethical clause coverage percentage, materials risk index, or supplier diversity spend was not explicitly stated with concrete numbers or percentages. While some articles mention vendor management policies, risk assessments for certain vendor categories (A and B), and the inclusion of compliance obligations in contracts for these categories

, no overall percentage of suppliers covered by such clauses is provided. Similarly, engagement in a 'Diversity Supplier Benchmark' is noted , but no specific procurement budget percentage is given.

Honest & Fair Business

Bioventus Inc. identified an immaterial error in its equity-based compensation expense for the fiscal year ended December 31, 2024, leading to a revision of previously issued financial statements.

This constitutes one restatement in the past year. The company has a Global Compliance Program, including a non-retaliation policy for good faith reporting, and provides phone numbers and an Ethics and Advice Line for reporting concerns. However, there is no evidence of independent investigation processes for these reports. Bioventus has a global Anti-Bribery and Anti-Corruption Policy, effective February 2018, which applies to all employees, contractors, and third parties. This policy prohibits facilitation payments, requires accurate record-keeping, and provides annual training to relevant employees. The company's vendor management policy also requires contracts to include clauses ensuring vendors agree to anti-bribery and anti-corruption policies and training standards. The company is a member of AdvaMed and follows its Code of Ethics and the MedTech Europe Code of Ethical Business Practice.

Kind to Animals

Bioventus uses bovine type I collagen in its MCS Bone Graft product, and there is no evidence of substitution with ethical alternatives, indicating zero percent substitution of animal-derived inputs.

The company conducts pre-clinical studies on animals to assess product safety, including rabbit studies for its MCS Bone Graft, with no evidence of alternative testing methods being employed. There is no mention of any products being certified cruelty-free. The company's policy explicitly states it conducts pre-clinical studies on animals to assess product safety, which is a vague policy that allows routine non-essential testing.

No War, No Weapons

Bioventus Inc. is a medical technology company focused on bone and joint healing, with products used in civilian medical procedures such as fracture repair and spinal fusion.

There is no evidence suggesting any revenue from arms or defense contracts, nor any involvement in dual-use technologies with military applications. The company's core business does not involve weapons, military, or defense activities. Its corporate description and product portfolio indicate no exposure to controversial weapons, and no need for ethical red lines related to weapons. The Board's Compliance and Ethics Committee oversees the company's general compliance and ethics program, which is appropriate given the absence of defense-related business.

Planet-Friendly Business

No specific quantitative data related to environmental performance metrics, regulatory actions, violations, fines, certifications, awards, or comparisons to industry benchmarks is provided in the available information.

The article focuses on general sustainability initiatives and employee engagement, indicating significant data gaps for all relevant metrics.

Respect for Cultures & Communities

The provided articles discuss Bioventus's general commitment to ethical conduct, compliance, and diversity, equity, and inclusion (DEI) initiatives, including DEI training, employee resource groups, and a DEI council.

The company also recognizes Juneteenth as a corporate holiday and has partnerships with Historically Black Colleges and Universities (HBCUs) and Cristo-Rey Work-Study programs. However, no specific quantitative data or concrete actions related to formal partnerships with indigenous or local community groups, revenue reinvested in local community development, cultural appropriation incidents, cultural impact assessment protocols, local employment ratios, community-specific grievance mechanisms, FPIC participation, community governance inclusion, cultural preservation investment, local procurement, indigenous supplier counts, cultural site protection, social license to operate, charitable giving to cultural heritage organizations, community fund allocation, language inclusivity, cultural incident response, or cultural sensitivity training completion percentages were found.

Safe & Smart Tech

Bioventus Inc. has reported no material cybersecurity incidents.

The company has a security awareness program for employees. Its privacy policy, effective April 17, 2024, outlines user rights to access, correct, and delete data. The policy also states that data is retained for legitimate business purposes and mentions compliance with GDPR and CCPA.

Zero Waste & Sustainable Products

The provided articles do not contain specific quantitative data for any of the Zero Waste & Sustainable Products KPIs. While general sustainability initiatives like IT equipment donation and a 'Meatless Mondays' program are mentioned,

there are no measurable outcomes, percentages, or targets related to waste diversion rates, product recyclability, packaging sustainability, or other relevant metrics required by the rubric.